To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Pregabalin BID Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.
Sponsor: Pfizer
This PHASE3 trial investigates Seizure Disorder, Partial and is currently completed. Pfizer leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Nov 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States, Alexandria, United States, Asheville, United States, Atlanta, United States, Bakersfield, United States, Baltimore, United States, Barrie, Canada, Bellevue, United States, Berkeley, United States, Brooklyn, United States and 68 more location s